Tag: earlystage

The top 12 VC firms most actively investing in early-stage AI startups

Posted on / by [email protected]_84 /

  • Artificial intelligence is one of the buzziest technologies of the past 20 years. 
  • Since 2000, investors have poured roughly $407 billion into AI startups, per data from PitchBook. 
  • In that time frame, the top 12 VC firms most active in early-stage AI investing by deal count have collectively closed a total of 708 Series A and B rounds, according to the data analytics firm. 
  • Visit Business Insider’s homepage for more stories.

Over the past two decades, artificial intelligence has quickly become one of the most buzzy technologies. 

Giants like IBM have doubled-down on AI-backed offerings, while a rush of startups have emerged that are trying to use the tech to overhaul operations ranging from stocking shelves to supply chain negotiations.

Along with that has come a bonanza of venture capital funding that has created so-called unicorns like Indigo Ag, UiPath, and SenseTime. In the past 20 years, investors have poured

… Read More

Identification of this epigenetic process highlights potential drug treatment strategies for early-stage disease treatment — ScienceDaily

Posted on / by [email protected]_84 /

New findings suggest that late-onset Alzheimer’s Disease is driven by epigenetic changes — how and when certain genes are turned on and off — in the brain. Results were published today in Nature Genetics.

Research led by Raffaella Nativio, PhD, a former research associate of Epigenetics, Shelley Berger, PhD, a professor of Genetics, Biology and Cell and Developmental Biology and Director of the Epigenetics Institute, and Nancy Bonini, PhD, a professor of Biology and Cell and Developmental Biology, all in the Perelman School of Medicine at the University of Pennsylvania, used post-mortem brain tissue to compare healthy younger and older brain cells to those with Alzheimer’s Disease. The team found evidence that epigenetic regulators disable protective pathways and enable pro-disease pathways in those with the disease.

“The last five years have seen great efforts to develop therapeutics to treat Alzheimer’s disease, but sadly, they have failed in the clinic

… Read More